Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ibrutinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK known ✓ | Q06187 | 14/20 | 1.00 |
| ▸ | EGFR | P00533 | 9/20 | 1.00 |
| ▸ | BMX | P51813 | 5/20 | 1.00 |
| ▸ | ITK | Q08881 | 4/20 | 1.00 |
| ▸ | TEC | P42680 | 3/20 | 1.00 |
| ▸ | HCK | P08631 | 3/20 | 1.00 |
| ▸ | SRC | P12931 | 3/20 | 1.00 |
| ▸ | BLK | P51451 | 3/20 | 1.00 |
| ▸ | TXK | P42681 | 2/20 | 1.00 |
| ▸ | LYN | P07948 | 2/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 2/20 | 1.00 |
| ▸ | NUDT5 | Q9UKK9 | 2/20 | 1.00 |
| ▸ | JAK3 | P52333 | 2/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 1/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
| ▸ | NUDT14 | O95848 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibrutinib SCHEMBL201641 | 1.00 | BTK (1.00) | BTKEGFRBMXITKTEC | |
| Ibrutinib SCHEMBL2244870 | 1.00 | BTK (1.00) | BTKEGFRBMXITKTEC | |
| Ibrutinib SCHEMBL201642 | 1.00 | BTK (1.00) | BTKEGFRBMXITKTEC | |
| Ibrutinib SCHEMBL2244865 | 1.00 | BTK (1.00) | BTKEGFRBMXITKTEC | |
| SCHEMBL21428758 | 0.98 | BTK (0.95) | BTKEGFRBMXITKTEC | |
| SCHEMBL200391 | 0.95 | BTK (1.00) | BTKEGFRBMXITKTEC | |
| SCHEMBL200392 | 0.95 | BTK (1.00) | BTKEGFRBMXITKTEC | |
| SCHEMBL201548 | 0.95 | BTK (1.00) | BTKEGFRBMXITKTEC | |
| Ibrutinib SCHEMBL16887867 | 0.95 | BTK (0.93) | BTKEGFRBMXITKTEC | |
| SCHEMBL1613606 | 0.93 | EGFR (0.90) | BTKEGFRBMXITKTEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9552 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4727596-A2 | ANTIBODY-DRUG CONJUGATES AND LINKERS AND METHODS OF USE THEREOF | Ohio State Innovation Foundation (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4729054-A1 | CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR | Pharmacyclics LLC (US) | 2026-04-22 | — | — | EP | claimed |
| EP-3856206-B1 | METHODS AND COMPOSITIONS FOR THE EXPANSION AND USE OF ALLOGENEIC GAMMA/DELTA-T CELLS | PHOSPHOGAM INC (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4531856-B1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | ALK ABELLO AS (DK) | 2026-04-22 | — | — | EP | claimed |
| US-20260102468-A1 | COMPOSITIONS AND METHODS FOR MARCO INHIBITION AND IMPROVED DRUG DELIVERY | UNIV TEXAS (US) | 2026-04-16 | — | — | US | claimed |
| EP-4724503-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS THROUGH INHIBITION OF CELL-IN-CELL PHENOMENON | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4203942-B1 | IBRUTINIB FOR USE IN TREATING COCAINE USE DISORDER AND RELATED CONDITIONS | UNIV EMORY (US) | 2026-04-15 | — | — | EP | claimed |
| EP-3897587-B1 | PHARMACEUTICAL COMPOSITION COMPRISING IBRUTINIB | SYNTHON BV (NL) | 2026-04-15 | — | — | EP | claimed |
| US-20100041677-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-02-18 | — | — | US | claimed |
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-28 | — | — | US | claimed |
| US-20100004270-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-07 | — | — | US | claimed |
| EP-2081435-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics, Inc. (US) | 2009-07-29 | — | — | EP | claimed |
| US-20090181987-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2009-07-16 | — | — | US | claimed |
| US-7514444-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2009-04-07 | — | — | US | claimed |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | claimed |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | PHARMACYCLICS, INC. (US) | 2008-05-08 | — | — | US | claimed |
| WO-2008039218-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-03-27 | — | — | US | claimed |